Global X S&P Biotech ETF (ASX:CURE)
Australia · Delayed Price · Currency is AUD 60.41
-0.98 (-1.60%)
At close: Feb 27, 2026
26.20% (1Y)
| Assets | 40.69M |
| Expense Ratio | 0.45% |
| PE Ratio | n/a |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | n/a |
| Payout Frequency | n/a |
| Payout Ratio | n/a |
| 1-Year Return | +26.20% |
| Volume | 1,120 |
| Open | 61.81 |
| Previous Close | 61.39 |
| Day's Range | 60.41 - 61.81 |
| 52-Week Low | 38.76 |
| 52-Week High | 65.95 |
| Beta | 0.36 |
| Holdings | 10 |
| Inception Date | Nov 8, 2018 |
About CURE
The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index.
Asset Class Equity
Category Health Care
Stock Exchange Australian Securities Exchange
Ticker Symbol CURE
Provider Global X
Index Tracked S&P Biotechnology Select Industry
Performance
CURE had a total return of 26.20% in the past year, including dividends. Since the fund's inception, the average annual return has been 6.21%.
Top Holdings
16.37% of assets| Name | Symbol | Weight |
|---|---|---|
| Moderna, Inc. | MRNA | 2.12% |
| Vaxcyte, Inc. | PCVX | 1.74% |
| Roivant Sciences Ltd. | ROIV | 1.70% |
| Mirum Pharmaceuticals, Inc. | MIRM | 1.63% |
| Arcellx, Inc. | ACLX | 1.63% |
| Praxis Precision Medicines, Inc. | PRAX | 1.59% |
| Revolution Medicines, Inc. | RVMD | 1.59% |
| Amgen Inc. | AMGN | 1.46% |
| Amicus Therapeutics, Inc. | FOLD | 1.46% |
| Gilead Sciences, Inc. | GILD | 1.45% |